Alaa Sada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alaa Sada has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Travis J. McKenzie
Department of Surgery, Mayo Clinic, Rochester, USA
9 shared publications Elizabeth B. Habermann
Division of Health Care Delivery Research, Mayo Clinic, Rochester, MN, USA
8 shared publicationsMelanie L. Lyden
Department of Surgery, Mayo Clinic, Rochester, MN, USA
8 shared publicationsBenzon M. Dy
Department of Surgery, Mayo Clinic, Rochester, MN, USA
6 shared publications- Elizabeth B. Habermann
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA
6 shared publications Travis J. McKenzie
Department of Surgery, Mayo Clinic, Rochester, MN, USA
4 shared publications
Latest Publications
- 7 November 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Clinical and Molecular Predictors of Malignancy in a Series of 585 RAS-positive Thyroid Nodules with Surgical Outcome
Context: RAS mutations are detected in a wide spectrum of thyroid tumors and when found on FNA biopsy, surgery is typically indicated. Objective: To identify clinical and molecular predictors of malignancy or non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in a consecutive series of RAS-positive thyroid nodules with known surgical outcome. Methods: We performed a single institution retrospective analysis of a consecutive series of RAS-positive thyroid nodules detected using ThyroSeqv3 and with either histopathology or ≥1 year follow-up ultrasound (2018-2024). Results: Totally, 585 RAS positive nodules with surgical pathology and 55 non-resected nodules were identified. After surgery 140/585 (24%) of nodules were benign, 149/585 (25%) NIFTP, and 296/585 (51%) cancer. The rate of cancer/NIFTP was lower in nodules with isolated KRAS mutations (34%) compared to isolated NRAS (74%) or HRAS (81%) (p<0.0001). The presence of copy number alterations (CNA) (OR 12, p=0.02), nodule size on ultrasound (OR 1.3, p=0.003) and higher Bethesda classification (IV, V or VI) were associated with cancer/NIFTP on multivariable analysis. On median follow-up of 2.5 years (IQR 1.2-4), persistent/recurrent disease occurred in 19/272 (7%) patients with a cancer diagnosis and was more likely with concurrent high-risk mutations (14/28, 50%) vs without (5/244, 2%), p<0.0001, with an even lower rate among isolated RAS cancers (1/133, 0.8%). After median 2.3 years (IQR 1.5-4.5), 6/55 nodules (11%) had significant growth. Conclusions: In this large series of RAS-positive tumors molecular and clinical factors predicted cancer. In isolated RAS-positive tumors, the rate of recurrent/persistent disease was very low with low rates of significant growth in non-resected nodules, suggesting that these nodules may be managed with lobectomy, and in select cases, even non-surgically.
- 7 November 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Clinical and Molecular Predictors of Malignancy in a Series of 585 RAS-positive Thyroid Nodules with Surgical Outcome
Context: RAS mutations are detected in a wide spectrum of thyroid tumors and when found on FNA biopsy, surgery is typically indicated. Objective: To identify clinical and molecular predictors of malignancy or non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in a consecutive series of RAS-positive thyroid nodules with known surgical outcome. Methods: We performed a single institution retrospective analysis of a consecutive series of RAS-positive thyroid nodules detected using ThyroSeqv3 and with either histopathology or ≥1 year follow-up ultrasound (2018-2024). Results: Totally, 585 RAS positive nodules with surgical pathology and 55 non-resected nodules were identified. After surgery 140/585 (24%) of nodules were benign, 149/585 (25%) NIFTP, and 296/585 (51%) cancer. The rate of cancer/NIFTP was lower in nodules with isolated KRAS mutations (34%) compared to isolated NRAS (74%) or HRAS (81%) (p<0.0001). The presence of copy number alterations (CNA) (OR 12, p=0.02), nodule size on ultrasound (OR 1.3, p=0.003) and higher Bethesda classification (IV, V or VI) were associated with cancer/NIFTP on multivariable analysis. On median follow-up of 2.5 years (IQR 1.2-4), persistent/recurrent disease occurred in 19/272 (7%) patients with a cancer diagnosis and was more likely with concurrent high-risk mutations (14/28, 50%) vs without (5/244, 2%), p<0.0001, with an even lower rate among isolated RAS cancers (1/133, 0.8%). After median 2.3 years (IQR 1.5-4.5), 6/55 nodules (11%) had significant growth. Conclusions: In this large series of RAS-positive tumors molecular and clinical factors predicted cancer. In isolated RAS-positive tumors, the rate of recurrent/persistent disease was very low with low rates of significant growth in non-resected nodules, suggesting that these nodules may be managed with lobectomy, and in select cases, even non-surgically.
- Open Access
- 20 November 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 255, 116740
Reoperative adrenalectomy: Indications and outcomes
- 20 November 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 255, 116740
Open AccessReoperative adrenalectomy: Indications and outcomes
- 5 November 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 315, 876-882
Reoperative Thyroid Procedures: Do They Pose a Higher Risk of Complications Compared to First-Time Surgery?
- 5 November 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 315, 876-882
Reoperative Thyroid Procedures: Do They Pose a Higher Risk of Complications Compared to First-Time Surgery?
- 13 March 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (4) , 1034-1039
Does Completion Thyroid Surgery Pose a Higher Risk of Complications?
Introduction: The outcomes of completion thyroidectomy are not well‐documented. The study aim is to compare the risks of total thyroidectomy (TT), thyroid lobectomy (TL), and completion thyroidectomy (CT) using a large multi‐institutional database.Methods: All cases of thyroidectomy without lymphadenectomy were identified using the CESQIP national database (2013–2023). Completion thyroidectomy was defined as contralateral lobectomy following previous lobectomy. Outcomes were examined including hematoma requiring evacuation, vocal cord dysfunction on post‐op laryngoscopy, and clinical concern for hypoparathyroidism.Results: Among 33,154 cases, TT, TL, and CT were performed in 19,057 (57%), 13,135 (40%) and 962 (3%), respectively. 30‐day hematoma rates were overall low: 135 (0.8%) in TT, 57 (0.5%) in TL, and < 10 (0.7%) in CT (p < 0.01). 30‐day vocal cord dysfunction was documented in 233 (1.4%), 159 (1.3%), and < 10 (1.0%) for TT, TL, and CT, respectively (p = 0.65). Temporary hypoparathyroidism was more common after TT than CT (989 (6%) versus 20 (2%), p < 0.01). Among 16,311 (49%) patients with reported long‐term outcomes, there were no differences in the rates of vocal cord dysfunction by type of operation (p = 0.34). However, long‐term hypoparathyroidism was more likely after TT than CT (237 (2.5%) versus < 10 (0.7%), p < 0.01).Conclusion: In this multi‐institutional endocrine surgery database, the reported long‐term complication rates after completion thyroidectomy were the same as for first‐time thyroid lobectomy. However, clinical hypoparathyroidism was 2.5‐fold more likely for total thyroidectomy than for completion thyroidectomy at 30‐days and remained 3.7‐fold higher in the long term suggesting that completion thyroidectomy does not pose a higher risk of complications.
- 13 March 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (4) , 1034-1039
Does Completion Thyroid Surgery Pose a Higher Risk of Complications?
Introduction: The outcomes of completion thyroidectomy are not well‐documented. The study aim is to compare the risks of total thyroidectomy (TT), thyroid lobectomy (TL), and completion thyroidectomy (CT) using a large multi‐institutional database.Methods: All cases of thyroidectomy without lymphadenectomy were identified using the CESQIP national database (2013–2023). Completion thyroidectomy was defined as contralateral lobectomy following previous lobectomy. Outcomes were examined including hematoma requiring evacuation, vocal cord dysfunction on post‐op laryngoscopy, and clinical concern for hypoparathyroidism.Results: Among 33,154 cases, TT, TL, and CT were performed in 19,057 (57%), 13,135 (40%) and 962 (3%), respectively. 30‐day hematoma rates were overall low: 135 (0.8%) in TT, 57 (0.5%) in TL, and < 10 (0.7%) in CT (p < 0.01). 30‐day vocal cord dysfunction was documented in 233 (1.4%), 159 (1.3%), and < 10 (1.0%) for TT, TL, and CT, respectively (p = 0.65). Temporary hypoparathyroidism was more common after TT than CT (989 (6%) versus 20 (2%), p < 0.01). Among 16,311 (49%) patients with reported long‐term outcomes, there were no differences in the rates of vocal cord dysfunction by type of operation (p = 0.34). However, long‐term hypoparathyroidism was more likely after TT than CT (237 (2.5%) versus < 10 (0.7%), p < 0.01).Conclusion: In this multi‐institutional endocrine surgery database, the reported long‐term complication rates after completion thyroidectomy were the same as for first‐time thyroid lobectomy. However, clinical hypoparathyroidism was 2.5‐fold more likely for total thyroidectomy than for completion thyroidectomy at 30‐days and remained 3.7‐fold higher in the long term suggesting that completion thyroidectomy does not pose a higher risk of complications.
- 29 October 2024
- Published by Springer Nature
- p. 213-218
Open Adrenalectomy: Techniques and Potential Complications
- 29 October 2024
- Published by Springer Nature
- p. 213-218
Open Adrenalectomy: Techniques and Potential Complications
- 21 October 2024
- Published by SAGE Publications in The American Surgeon™
- Vol. 91 (3) , 381-385
Oncocytic Adrenal Neoplasms: Clinical Profiles and Long-Term Outcomes
Background: Oncocytic adrenal neoplasms, defined by ≥90 % of oncocytic cells, are rare. The significance of oncocytic changes within an adrenal neoplasm remains unclear. Methods: A retrospective study of adults who underwent adrenalectomy at a large center identified pure oncocytic neoplasms on final pathology (1997-2022). Neoplasms were categorized based on Lin-Weiss-Bisceglia system as malignant, benign, or of uncertain malignant potential. Analysis was performed using Fisher exact, Kruskal-Wallis tests, and Kaplan-Meier analysis. Results: Among a total of 33 patients, 24% had benign, 36% malignant, and 39% neoplasm of uncertain malignant potential. None of the benign neoplasms recurred, while 50% of the malignant neoplasms recurred (median of 40 months). Two of 13 neoplasms initially thought to be of uncertain malignant potential recurred as distant metastatic adrenocortical carcinoma at 11 and 25 months, over a median follow-up duration of 31 months. Ki67% was available for 20 patients: median (IQR) Ki67% was 5 (1, 5) for benign, 10 (6, 15) for malignant, and 6.5 (5, 10) for neoplasms of uncertain behavior, P = 0.05. Recurred neoplasms had higher Ki67% at initial resection compared to cases that did not recur. Conclusion: While oncocytic adrenal neoplasms are rare, a significant proportion are malignant or have malignant potential. Judicious follow-up is required for oncocytic adrenal neoplasms of uncertain malignant potential, as they can recur as metastatic adrenocortical carcinoma. Ki67% should always be obtained in cases of malignancy or uncertain malignant potential as it can predict recurrence. Larger studies are needed to evaluate the appropriate follow-up protocols for these neoplasms.
- 21 October 2024
- Published by SAGE Publications in The American Surgeon™
- Vol. 91 (3) , 381-385
Oncocytic Adrenal Neoplasms: Clinical Profiles and Long-Term Outcomes
Background: Oncocytic adrenal neoplasms, defined by ≥90 % of oncocytic cells, are rare. The significance of oncocytic changes within an adrenal neoplasm remains unclear. Methods: A retrospective study of adults who underwent adrenalectomy at a large center identified pure oncocytic neoplasms on final pathology (1997-2022). Neoplasms were categorized based on Lin-Weiss-Bisceglia system as malignant, benign, or of uncertain malignant potential. Analysis was performed using Fisher exact, Kruskal-Wallis tests, and Kaplan-Meier analysis. Results: Among a total of 33 patients, 24% had benign, 36% malignant, and 39% neoplasm of uncertain malignant potential. None of the benign neoplasms recurred, while 50% of the malignant neoplasms recurred (median of 40 months). Two of 13 neoplasms initially thought to be of uncertain malignant potential recurred as distant metastatic adrenocortical carcinoma at 11 and 25 months, over a median follow-up duration of 31 months. Ki67% was available for 20 patients: median (IQR) Ki67% was 5 (1, 5) for benign, 10 (6, 15) for malignant, and 6.5 (5, 10) for neoplasms of uncertain behavior, P = 0.05. Recurred neoplasms had higher Ki67% at initial resection compared to cases that did not recur. Conclusion: While oncocytic adrenal neoplasms are rare, a significant proportion are malignant or have malignant potential. Judicious follow-up is required for oncocytic adrenal neoplasms of uncertain malignant potential, as they can recur as metastatic adrenocortical carcinoma. Ki67% should always be obtained in cases of malignancy or uncertain malignant potential as it can predict recurrence. Larger studies are needed to evaluate the appropriate follow-up protocols for these neoplasms.
- 13 October 2023
- Published by Elsevier in Journal of Surgical Research
- Vol. 293, 663-669
Ethanol Ablation for Benign Insulinoma: Intraoperative and Endoscopic Approaches
- 13 October 2023
- Published by Elsevier in Journal of Surgical Research
- Vol. 293, 663-669
Ethanol Ablation for Benign Insulinoma: Intraoperative and Endoscopic Approaches
- 1 July 2023
- Published by Elsevier in Journal of Surgical Research
- Vol. 291, 151-157
Disparities in Parathyroidectomy: Who Receives Appropriate Treatment for Primary Hyperparathyroidism?
- 1 July 2023
- Published by Elsevier in Journal of Surgical Research
- Vol. 291, 151-157
Disparities in Parathyroidectomy: Who Receives Appropriate Treatment for Primary Hyperparathyroidism?
- 17 March 2023
- Published by Springer Nature
- p. 359-370
Acute and Chronic Postoperative Hernia Complications and Changes
- 17 March 2023
- Published by Springer Nature
- p. 359-370
Acute and Chronic Postoperative Hernia Complications and Changes